Jun 25, 2025, 08:20
TOP Biotechs at ASCO: Akshay Nanduri on AI Imaging Models for Lung Cancer Clinical Trials
In this episode of TOP Biotechs at ASCO, Akshay Nanduri, Co-founder and CEO of OncAI, discusses how his company is transforming oncology clinical management through advanced AI solutions.
OncAI is built on a simple but powerful premise: routine diagnostic imaging—such as CT scans—is underutilized in both clinical care and clinical trials. By unlocking hidden insights within these scans through AI, OncAI helps pharma companies and oncologists make more informed decisions that can improve outcomes for cancer patients.
Key topics covered:
- Why standard imaging protocols like RECIST leave valuable insights untapped
- OncAI’s AI-powered tools for optimizing clinical trial decisions
- Current products: one under FDA review, one with FDA breakthrough designation
- How OncAI’s models outperform RECIST in predicting overall survival in metastatic non-small cell lung cancer
- AI’s growing role in driving precision oncology and clinical trial success
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 16, 2025, 17:55
Jul 16, 2025, 17:38
Jul 16, 2025, 17:37
Jul 16, 2025, 17:04
Jul 16, 2025, 16:51
Jul 16, 2025, 16:34
Jul 16, 2025, 16:18